Τίτλος:
ABREAST: a prospective, real-world study on the effect of nab-paclitaxel treatment on clinical outcomes and quality of life of patients with metastatic breast cancer
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Purpose: The efficacy of nab-paclitaxel in patients with metastatic breast cancer (MBC) has been demonstrated in randomized clinical trials. However, real-world evidence on effectiveness remains limited. Patients and methods: The primary objective of this multicenter prospective study was to assess the overall response rate (ORR) of patients with MBC treated with nab-paclitaxel. Secondary objectives included progression-free survival (PFS), overall survival (OS) and quality of life, assessed with the Functional Assessment of Cancer Therapy-Breast (FACT-B) instrument. Results: Eligible patients (N = 150; 36% with de novo MBC presentation) with a median age of 64.5 years were enrolled (86% were ER+, 33.3% (50/150) were ≥ 70 years of age and 53% were treated in the third or later line of treatment). A median of 6 cycles were administered but 26% of patients required dose reduction due to toxicity. The ORR was 26.7% [95% confidence interval (CI) 19.6–33.7], the median PFS was 6.2 months (95% CI 5.2–7.3), and the median OS 21.1 months (95% CI 17.2-not estimable). There was no statistical significant difference in the median PFS of patients < and ≥ 70 years of age. The patients’ baseline FACT-B total score remained unchanged. The serious and non-serious adverse event incidence rates were 13% and 48%, respectively. Conclusions: This prospective study provides further evidence on quality of life, efficacy, and safety of nab-paclitaxel in patients with MBC and sheds more light in special subpopulations such as the elderly and those treated beyond the second line. © 2020, Springer Science+Business Media, LLC, part of Springer Nature.
Συγγραφείς:
Koumarianou, A.
Makrantonakis, P.
Zagouri, F.
Papadimitriou, C.
Christopoulou, A.
Samantas, E.
Christodoulou, C.
Psyrri, A.
Bafaloukos, D.
Aravantinos, G.
Papakotoulas, P.
Baka, S.
Andreadis, C.
Alexopoulos, A.
Bompolaki, I.
Kampoli, Κ.
Liori, S.
Karvounis, K.
Ardavanis, A.
Περιοδικό:
Breast Cancer Research and Treatment
Λέξεις-κλειδιά:
aspartate aminotransferase; paclitaxel; 130-nm albumin-bound paclitaxel; albuminoid; epidermal growth factor receptor 2; ERBB2 protein, human; estrogen receptor; paclitaxel; progesterone receptor, adult; age distribution; aged; Article; backache; bone metastasis; cancer growth; cancer survival; clinical effectiveness; clinical outcome; dizziness; drug safety; dysesthesia; dyspnea; fatigue; febrile neutropenia; female; Functional Assessment of Cancer Therapy Breast Instrument; Greece; heart infarction; human; hypocalcemia; liver failure; liver metastasis; lung metastasis; major clinical study; metastatic breast cancer; multicenter study; multiple cycle treatment; myalgia; nausea; neuritis; neutropenia; overall survival; pleura effusion; priority journal; progression free survival; prospective study; quality of life; quality of life assessment; side effect; treatment outcome; treatment response; vein insufficiency; vestibular disorder; vomiting; breast tumor; clinical trial; follow up; lobular carcinoma; metabolism; middle aged; mortality; Paget nipple disease; pathology; prognosis; survival rate, Aged; Albumins; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Female; Follow-Up Studies; Humans; Middle Aged; Paclitaxel; Prognosis; Prospective Studies; Quality of Life; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate
DOI:
10.1007/s10549-020-05677-4
